Conivaptan · Vaprisol In 5% Dextrose In Plastic Container, YM087

What is Conivaptan?

Conivaptan is a dual arginine vasopressin (AVP) antagonist that binds V1A and V2 receptors with nanomolar affinity. It antagonizes V2 receptors in renal collecting ducts, promoting aquaresis and free water excretion to raise serum sodium in hyponatremia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Vaprisol In 5% Dextrose In Plastic Container, YM087, Vaprisol

Drug type

Small molecule

Targets

Vasopressin V1A receptor (AVPR1A), Vasopressin V2 receptor (AVPR2)

Mechanism

Antagonist of Vasopressin V1A receptor (AVPR1A) and Vasopressin V2 receptor (AVPR2)

Pathways

aquaporin channel regulation, water reabsorption

Therapy area

Metabolic

Developer

Apotex

In trials of

CPIX

FDA status

Approved as Vaprisol In 5% Dextrose In Plastic Container (December 29, 2005), NDA021697 · FDA label

UNII

0NJ98Y462X

✅ FDA-approved uses

• Euvolemic hyponatremia
• Hypervolemic hyponatremia

From the indications section of the FDA label (version of Dec 29, 2023). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hyponatremia

Other drugs acting on AVPR1A / AVPR2

Sources

• FDA label (DailyMed)
• FDA label Vaprisol In 5% Dextrose In Plastic Container (2023-12-29), indications

Updated Oct 3, 2026.